Official ESCRS | European Society of Cataract & Refractive Surgeons
Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Posters

Search Title by author or title

Effect of topical prednisolone acetate 1 % on intraoperative mydriasis and postoperative pain following cataract surgery

Poster Details

First Author: M. Shoja IRAN, ISLAMIC REPUBLIC OF

Co Author(s):    H. Safi   M. Mahdavi                 

Abstract Details

Purpose:

To study the effect of topical prednisolone acetate 1 % on intraoperative mydriasis and postoperative pain following cataract surgery.

Setting:

This prospective study was investigated on patients candidated for cataract surgery from March 2015 to June 2015 at Shahid Sadoughi hospital, Yazd, Iran Patients who have mature cataract, pseudoexfoliation syndrome, diabetes and history of alpha -blockers or anti-glaucoma medications were excluded.

Methods:

Patients were divided into case (treated with topical Prednisolone acetate 1 % every 6 hours for one day before surgery) and control (treated with artificial tears every 6 hours for one day before surgery) groups. All patients underwent phacoemulsification by single surgeon. Pupillary diameter measured prior and at the end of surgery. Postoperative pain was assessed using visual analogue scale for pain.

Results:

The study enrolled 20 cases and 20 controls. There was no significant difference between the mean of preoperative mydriasis between two groups. Patients treated with prednisolone acetate 1 % showed significant larger mean of pupillary diameter (7.45 mm) postoperatively than control group (5.70 mm) and significant lower postoperative pain (P<0.001).

Conclusions:

Application of prednisolone acetate 1 % before cataract surgery showed promising results in intraoperative mydriasis maintenance and postoperative pain relief.

Financial Disclosure:

NONE

Back to Poster listing